An Astra Zeneca logo is pictured in Brussels, Belgium March 4, 2024. Yves Herman
An Astra Zeneca logo is pictured in Brussels, Belgium March 4, 2024. Yves Herman

AstraZeneca's rare disease drug misses main goal in late-stage trial

July 27th, 2026 | 07:01 AM BUSINESS Healthcare & Pharmaceuticals 1

Facebook Twitter Google+ LinkedIn Pinterest
By Reuters

AstraZeneca (AZN.L) said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with ​a blood vessel complication following a stem cell transplant, ‌the latest in a series of setbacks this year that have fuelled concerns about the drugmaker's pipeline.

Here are some details:

Related Posts

© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT